Manchester Capital Management’s Adial Pharmaceuticals ADIL Stock Holding History

Manchester Capital Management’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.92K	Hold	1,923	–	–	﹤0.01%	899
2026 Q1	$3.44K	Sell	1,923 -1	-0.1%	-$4	﹤0.01%	931
2025 Q4	$10.6K	Hold	1,924	–	–	﹤0.01%	773
2025 Q3	$17K	Hold	1,924	–	–	﹤0.01%	772
2025 Q2	$14.5K	Hold	1,924	–	–	﹤0.01%	780
2025 Q1	$30.5K	Hold	1,924	–	–	﹤0.01%	638
2024 Q4	$48.6K	Hold	1,924	–	–	0.01%	542
2024 Q3	$48K	Hold	1,924	–	–	0.01%	546
2024 Q2	$55.3K	Hold	1,924	–	–	0.01%	479
2024 Q1	$64K	Hold	1,924	–	–	0.01%	445
2023 Q4	$89.5K	Hold	1,924	–	–	0.01%	368
2023 Q3	$134K	Hold	1,924	–	–	0.02%	315
2023 Q2	$250K	Hold	1,924	–	–	0.03%	248
2023 Q1	$421K	Buy	+1,924	New	+$466K	0.06%	201

Other funds holding ADIL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Manchester Capital Management's ADIL Position: Q2 2026 in Review

Manchester Capital Management held its Adial Pharmaceuticals (ADIL) position steady in Q2 2026 at 1,923 shares worth $4.92K. The position accounts for ﹤0.01% of the portfolio, ranked #899.

Manchester Capital Management first reported a position in ADIL in Q1 2023 and has held it in 14 quarters since. The position peaked at $421K in Q1 2023. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

Manchester Capital Management held 1,923 shares of Adial Pharmaceuticals worth $4.92K as of Q2 2026.
Manchester Capital Management left its Adial Pharmaceuticals share count unchanged in Q2 2026.
Adial Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #899 holding.
Manchester Capital Management first reported a position in Adial Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Manchester Capital Management's Adial Pharmaceuticals position peaked at $421K in Q1 2023.
17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.